Suggested slug: pancragen-research-guide

Status: Locked citation-verified draft. Not published. Not for WordPress.

Research-use-only framing. This page describes a short peptide bioregulator sold as a laboratory research material. It is not medical advice. Simple Research Peptides (SRP) materials are for laboratory research only and are not for human or veterinary use, consumption, administration, diagnosis, treatment, or therapeutic application.

One-sentence identity. Pancragen is a Khavinson-catalog synthetic tetrapeptide printed in opened papers as Lys-Glu-Asp-Trp (KEDW) and, on other opened pages, as the C-terminal amide Lys-Glu-Asp-Trp-NH2 (KEDW-NH2); it is positioned as a short “peptide bioregulator” associated with pancreatic-cell / gene-expression research; English-language independently replicated evidence is limited, ClinicalTrials.gov returned 0 studies for the trade name or KEDW, and it is not Livagen, not Ovagen, not Pinealon, not Vesugen, not Chonluten, and not insulin, glucagon, amylin, or cagrilintide.

–-

SRP product and index pages do not print a sequence, CAS, UNII, molecular formula, or a public COA. The sequences below are taken only from opened primary papers and from opened PubChem records that match those printed sequences. PubChem does not list the trade name Pancragen as a synonym on either CID opened here.

What this is chemically, from opened pages. Opened Khavinson-group papers print Pancragen as a four-residue peptide built from lysine, glutamic acid, aspartic acid, and tryptophan. They do not agree on the C-terminus. PMID 25946840 and PMID 22808515 print Lys-Glu-Asp-Trp. PMID 18642713 prints Lys-Glu-Asp-Trp-NH2. PMID 35887081 Table 2 prints Pancragen (KEDW-NH2). Several Europe PMC chemical lists use the MeSH string lysyl-glutamyl-aspartyl-tryptophanamide. Those are not the same terminal chemistry. This draft records both printings and does not collapse them.

PubChem has matching structures under sequence titles, not under the marketplace name:

• CID 68452877 = free acid H-Lys-Glu-Asp-Trp-OH / KEDW / C26H36N6O9 / 576.6 Da.
• CID 68451868 = amide H-Lys-Glu-Asp-Trp-NH2 / C26H37N7O8 / 575.6 Da.

Neither CID prints “Pancragen.” Neither CID prints a CAS or UNII.

What this is not, chemically.

• Not Livagen (KEDA / Lys-Glu-Asp-Ala). Same 2022 table, different row (ICM −22.01, “Hepatoprotector”).
• Not Ovagen (EDL). Same table, labeled nephro-/hepatoprotector.
• Not Pinealon (EDR). Same table, labeled neuroprotector.
• Not Vesugen (KED). Same table, labeled vasoprotector. PMID 22808515 tests vesugen on fibroblasts in the same design that tests pancragen on pancreatic cells.
• Not Chonluten (EDG). Same table, labeled gastroprotector / stress protector.
• Not Bronchogen (AEDL on that table). PMID 22808515 and PMID 25761685 pair KEDW with AEDL as tissue-specific counterparts (pancreas vs bronchi).
• Not insulin, glucagon, amylin, pramlintide, or cagrilintide. Those are endogenous or analogue hormones / receptor agonists. Pancragen is a four-residue Khavinson cytogen-style peptide. Do not transfer GLP-1 / amylin-receptor trial evidence.
• Not the vendor CID 68452887 (a fluorinated benzimidazole, C25H18FN3O4).
• Not CAS 45234-02-4 (lysylglutamic acid, the KE dipeptide).
• Not shown on any opened page to be compositionally identical to an SRP 20 mg lyophilized research vial. SRP itself tells the buyer to “verify sequence, salt form, and assay.”

Not printed on SRP pages and therefore not claimed as SRP-verified: sequence, free-acid vs amide status, CAS, UNII, formula, CID, or purity numbers. The product page does not print a public COA.

Pankragen-forte. PMID 28976155 is an opened Russian-language abstract about an oral product spelled pankragen-forte in 12 older adults with impaired glucose tolerance. That abstract does not print Lys-Glu-Asp-Trp or KEDW. It is logged as a related trade-name variant, not as confirmed identity for an SRP vial and not as a diabetes-treatment claim.

–-

Pancragen (this page) is the tetrapeptide Lys-Glu-Asp-Trp / KEDW, sometimes printed as the amide, on the opened Khavinson / Goncharova / Korkushko pages. It is one name inside the Khavinson / cytomedin-style short-peptide bioregulator catalog. That catalog is a research-network taxonomy, not a receptor-class assignment.

–-

Product URL: http://simpleresearchpeptides.com/product/pancragen-20-mg/

Fetched page title: “Pancragen 20 mg Research Peptide Vial”. Breadcrumb/tags: Metabolic Research, Peptide Bioregulators, Research Peptides. Body: “one 20 mg research vial; verify sequence, salt form, and assay. Organized for pancreatic-tissue models, metabolic signaling, and peptide-bioregulator characterization. For laboratory research use only.” Research material: Pancragen. Listed strength and format: 20 mg. Research category: Metabolic Research. Disclaimer: “For laboratory research only. Not for human or animal use, consumption, administration, diagnosis, treatment, or therapeutic application.” Reviews (0). A dollar price was not printed in the fetched markdown.

Index card on http://simpleresearchpeptides.com/research-compound-directory/compound-research-guides/: Metabolic → “Pancragen 20 mg”; Evidence profile (not a dedicated long-form guide). Evidence tag on the same index body: Sparse/limited evidence. Overview text on that index: Pancragen is a short peptide bioregulator associated with pancreatic-tissue research in regional literature. Mechanism under study: proposed actions involve gene-expression regulation and tissue homeostasis, but a broadly accepted molecular target has not been established. Evidence summary: evidence is primarily preclinical or from small, regionally published studies; independent replication and standardized human safety data are limited. Research-quality note: confirm the exact peptide sequence and avoid extrapolating from general pancreatic peptides. Last editorial review printed on that index: August 2026.

Dedicated guide URL http://simpleresearchpeptides.com/research-compound-directory/pancragen-research-guide/ returned HTTP 404 on 16 August 2026.

Educational information only. No human dosing, reconstitution, or administration protocol appears on this page.

–-

Pancragen is a synthetic tetrapeptide from the St. Petersburg Institute of Bioregulation and Gerontology catalog. Opened papers report four clusters of laboratory observations:

1. Tissue-specific explant / culture effects on pancreatic tissue (Zakutskii et al. 2006, PMID 17152728; Khavinson et al. 2012, PMID 22808515).
2. Differentiation-factor expression in aging pancreatic cell cultures — Pdx1, Ptf1a, Pax6, Pax4, Foxa2, Nkx2.2 and related markers (Khavinson et al. 2013, PMID 23486591; review-level restatement in PMID 31808038).
3. Promoter-methylation / DNA-binding language for the letters KEDW (Ashapkin et al. 2015, PMID 25761685; Khavinson et al. 2016, PMID 27909961; Khavinson et al. 2021, PMID 34834147 citing the 2015 *Am. J. Biomed. Sci.* KEDW–DNA paper).
4. Glucose / insulin / C-peptide readouts in streptozotocin rats (PMID 18642713), aged rhesus monkeys (PMID 25946840; PMID 28509500), and two small regional human reports (PMID 22448364; the separately spelled pankragen-forte abstract PMID 28976155).

Almost all indexed work originates from the Khavinson network and collaborators in St. Petersburg, Sochi (Research Institute of Medical Primatology), and Kiev (Institute of Gerontology). No opened Western independent replication of the differentiation-factor or primate glucose-tolerance findings was located. ClinicalTrials.gov has no Pancragen or KEDW study.

This is not a diabetes medicine, not an insulin secretagogue class, and not a substitute for approved metabolic drugs. Opened abstracts that use treatment-style language are recorded as author claims from those papers, not as SRP indications.

–-

Observed in opened Pancragen- or KEDW-named papers

• Tissue-specific differentiation-marker stimulation in aging cultures. Pancragen (Lys-Glu-Asp-Trp) “tissue-specifically stimulated” CXCL12 and Hoxa3 in human embryonic pancreatic-cell cultures; the effect was “more pronounced in aged cultures.” Bronchogen and vesugen acted on bronchial epithelium and fibroblasts, respectively, in the same design (Khavinson et al. 2012, PMID 22808515).
• Acinar and islet transcription-factor panel. “Tetrapeptide pancragen stimulates the expression of differentiation factors of acinar (Pdx1, Ptfla) and islet of Langerhans (Pdx1, Pax6, Pax4, Foxa2, NKx2.2) cells in ‘young’ and ‘aged’ cultures” (Khavinson et al. 2013, PMID 23486591). The opened abstract then uses treatment-style language (“anti-diabetic,” “treatment of diabetes mellitus and pancreatitis”). That language is the authors’ interpretation. It is not a registered trial and is not adopted here as a clinical claim.
• KEDW and promoter methylation in pancreatic cultures. KEDW “tissue-specifically” affected gene expression in pancreatic (not bronchial) cultures. Promoter methylation of PDX1, PAX6, and NGN3 changed with culture aging and with KEDW in a pattern that correlated with expression; PAX4 methylation did not change even though expression did; FOXA2 methylation changed without correlating with expression (Ashapkin et al. 2015, PMID 25761685). The opened abstract does not print the trade name Pancragen.
• In-silico DNA-site language. Docking models in Khavinson, Lin’kova, Tarnovskaya 2016 (PMID 27909961) place KEDW and AED on an acct sequence. The 2021 systematic review (PMID 34834147, PMC8619776) restates that KEDW increased expression of PDX1, NGN3, MNX1, PAX6, FOXA2, NKX2-2, NKX6.1, HOXA3, and PAX4 and cites the 2015 *American Journal of Biomedical Sciences* paper (DOI 10.5099/aj150300156) for DNA-binding / ACCT-promoter language. That 2015 journal article was not itself opened in this pass; claims beyond what PMID 34834147 printed are not used.
• In-silico LAT1 docking (not a transport assay). Pancragen (KEDW-NH2) ICM-score −23.47 on LAT1 (Khavinson et al. 2022, PMID 35887081, Table 2). Follow-up docking of KEDW-NH2 (trade name Pancragen not printed in the 2023 methods list): LAT1 (PDB 6IRT) −28.40; LAT2 (7B00) −21.78; PEPT1 (7PN1) −20.57; PEPT2 (7PMY) +6.90 (Khavinson et al. 2023, PMID 36979488, PMC10046148, Tables 1, 3, 5, 7). The same 2022 paper states KEDW (with KEDA) was “resistant to hydrolysis for 3–4 h in physiological saline, Ringer’s solution, HCl and tissue homogenates,” citing prior hydrolysis work. This is docking / review language, not a measured PEPT/LAT flux for Pancragen.
• Organotypic pancreas explants. Pancragen, grouped with cardiogen, bronchogen, and prostamax, “showed a stimulating effect in appropriate tissue cultures” at the printed explant concentration in young and old rats (Zakutskii et al. 2006, PMID 17152728). Sequence is not printed on that opened abstract.

Glucose-axis observations (preclinical / small regional human; not treatment claims)

• Streptozotocin Wistar rats: opened abstract of PMID 18642713 reports that oral pancragen (printed as Lys-Glu-Asp-Trp-NH2) changed blood glucose during treatment and that intramuscular pancragen changed mesenteric capillary endothelial adhesion without changing permeability. This is a rodent chemical-diabetes model.
• Aged female rhesus monkeys: opened abstract of PMID 25946840 prints Lys-Glu-Asp-Trp and reports faster glucose disappearance and normalized insulin / C-peptide peaks after a 10-day intramuscular course, with a partial effect remaining three weeks later. PMID 28509500 is a related old-monkey comparison with oral glimepiride (n=5 pancragen, n=4 glimepiride). Those are primate laboratory studies, not human trials.
• Elderly humans with type 2 diabetes (Korkushko et al. 2011, PMID 22448364): opened abstract reports 30 healthy older persons and 33 patients with type 2 diabetes; nocturnal melatonin described as reduced in the diabetes group; the pancragen arm is described as decreasing fasting and OGTT glucose, plasma insulin, and an insulin-resistance index, with no change in the no-pancragen subgroup. Route, duration, randomization, and blinding are not stated in the opened abstract. Not an NCT.
• Pankragen-forte (PMID 28976155): 12 older adults with impaired glucose tolerance; oral product; opened abstract describes OGTT glucose falling in “50 percent” of that group. Sequence not printed. Not an NCT. Not used as SRP-vial identity.

Not shown in a paper opened here

• A defined cell-surface receptor (IUPHAR: no ligand).
• Measured LAT1 / PEPT1 flux of Pancragen in a wet assay.
• Pharmacokinetics, oral bioavailability, or human safety package for a research vial.
• Equivalence of free-acid KEDW and KEDW-NH2 in the same experiment.
• Equivalence of an SRP lyophilized vial to the material used in any cited paper.
• Independent Western replication.

–-

Evidence quality overall: sparse / limited. One research network. Small n. Several Russian-language abstracts. No registered trial.

Opened and not used as Pancragen evidence: Europe PMC pancragen also returned pancreatic-cyst / IPMN / pancreatic-cancer papers (e.g. PMID 37749004, 41090355, 33207417, 32050465, 35229208, 28739154, 35854467, 36600097, 38472986, 31676330). Those are lexical collisions on “pancrea-”. Unused.

–-

• Not Livagen (KEDA), Ovagen (EDL), Pinealon (EDR), Vesugen (KED), Chonluten (EDG), Epitalon (AEDG), Vilon (KE), Bronchogen (AEDL), or Prostamax / Prostomax (KEDP).
• Not insulin, proinsulin, C-peptide, glucagon, GLP-1, GIP, amylin, pramlintide, or cagrilintide.
• Not a pancreatic tissue extract (the older cytomedin-style pancreas complex sometimes sold as Suprefort in other catalogs was not opened as a primary identity source and is not treated as the same molecule).
• Not an FDA-approved drug. openFDA 404. NCATS 0. IUPHAR 404. UNII none. NCT none.
• Not CID 68452887.
• Not CAS 45234-02-4 or the unverified vendor CAS 8057-49-6.
• Not a human diabetes, pancreatitis, or prediabetes treatment. This page does not provide dosing or reconstitution.

–-

• SRP listing is a 20 mg research vial for laboratory evaluation in pancreatic-tissue models, metabolic signaling, and peptide-bioregulator characterization.
• Confirm sequence and C-terminus (free acid KEDW vs KEDW-NH2) on the certificate of analysis. Opened literature uses both.
• Do not assume a trade name equals a PubChem CID. The name pancragen is not a PubChem title.
• Do not copy rodent, monkey, or regional-human exposure details as a laboratory or human protocol.
• Do not merge evidence from insulin, GLP-1, or amylin analogues.
• Independent replication, pharmacokinetics, and standardized human safety data are limited.

–-

–-

Pancragen 20 mg — http://simpleresearchpeptides.com/product/pancragen-20-mg/ Opened page title: “Pancragen 20 mg Research Peptide Vial”. Breadcrumb/tags: Metabolic Research, Peptide Bioregulators, Research Peptides. Lead line: “one 20 mg research vial; verify sequence, salt form, and assay. Organized for pancreatic-tissue models, metabolic signaling, and peptide-bioregulator characterization. For laboratory research use only.” Description: research material Pancragen; listed strength and format 20 mg; research category Metabolic Research. Footer: “For laboratory research only. Not for human or animal use, consumption, administration, diagnosis, treatment, or therapeutic application.” Reviews (0). Sequence, CAS, UNII, molecular formula, price, and a public COA were not printed on the fetched markdown.

Index entry — http://simpleresearchpeptides.com/research-compound-directory/compound-research-guides/ Listing: “Pancragen 20 mg” under Metabolic; “Evidence profile.” Evidence tag: Sparse/limited evidence. Last editorial review printed: August 2026.

Dedicated guide — http://simpleresearchpeptides.com/research-compound-directory/pancragen-research-guide/ HTTP 404 on 16 August 2026.

–-

Sources actually opened for this draft:

1. Zakutskii AN, Chalisova NI, Ryzhak GA, Aniskina AI, Filippov SV, Zeziulin PN. The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats. *Adv Gerontol.* 2006;19:93–96. PMID 17152728.
2. Khavinson VKh, Gavrisheva NA, Malinin VV, Chefu SG, Trofimov EL. Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus. *Bull Exp Biol Med.* 2007;144(4):559–562. PMID 18642713. DOI 10.1007/s10517-007-0377-3.
3. Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA, Bondarenko EV. Prospects of using pancragen for correction of metabolic disorders in elderly people. *Bull Exp Biol Med.* 2011;151(4):454–456. PMID 22448364. DOI 10.1007/s10517-011-1354-4.
4. Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Peptides tissue-specifically stimulate cell differentiation during their aging. *Bull Exp Biol Med.* 2012;153(1):148–151. PMID 22808515. DOI 10.1007/s10517-012-1664-1.
5. Korkushko OV, Chizhova VP, Shatilo VB, Khavinson VK. The tetrapeptide pankragen forte efficiency in elderly people with prediabetic state. *Adv Gerontol.* 2013;26(2):297–308. PMID 28976155. Pankragen-forte spelling; sequence not on opened abstract.
6. Khavinson VKh, Durnova AO, Polyakova VO, Tolibova GH, Linkova NS, Kvetnoy IM, Kvetnaia TV, Tarnovskaya SI. Effects of pancragen on the differentiation of pancreatic cells during their ageing. *Bull Exp Biol Med.* 2013;154(4):501–504. PMID 23486591. DOI 10.1007/s10517-013-1987-6.
7. Goncharova ND, Ivanova LG, Oganian TE, Vengerin AA, Khavinson VKh. Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys. *Adv Gerontol.* 2014;27(4):662–667. PMID 25946840.
8. Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. *Biochemistry (Mosc).* 2015;80(3):310–322. PMID 25761685. DOI 10.1134/s0006297915030062.
9. Goncharova ND, Ivanova LG, Oganyan TE, Vengerin AA, Khavinson VK. Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys. *Adv Gerontol.* 2015;28(3):579–585. PMID 28509500.
10. Khavinson VK, Lin’kova NS, Tarnovskaya SI. Short peptides regulate gene expression. *Bull Exp Biol Med.* 2016;162(2):288–292. PMID 27909961. DOI 10.1007/s10517-016-3596-7.
11. Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide regulation of cell differentiation. *Stem Cell Rev Rep.* 2020;16(1):118–125. PMID 31808038. DOI 10.1007/s12015-019-09938-8.
12. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. *Molecules.* 2021;26(22):7053. PMID 34834147. PMC8619776. DOI 10.3390/molecules26227053.
13. Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of biologically active ultrashort peptides using POT and LAT carriers. *Int J Mol Sci.* 2022;23(14):7733. PMID 35887081. PMC9323678. DOI 10.3390/ijms23147733. Table 2: Pancragen (KEDW-NH2), ICM −23.47.
14. Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of transport of 26 biologically active ultrashort peptides via LAT and PEPT family transporters. *Biomolecules.* 2023;13(3):552. PMID 36979488. PMC10046148. DOI 10.3390/biom13030552.
15. PubChem CID 68452877 (H-Lys-Glu-Asp-Trp-OH; C26H36N6O9; InChIKey PIGJHNNSOMRLST-LEAZDLGRSA-N). https://pubchem.ncbi.nlm.nih.gov/compound/68452877 and PUG REST (opened 16 August 2026).
16. PubChem CID 68451868 (H-Lys-Glu-Asp-Trp-NH2; C26H37N7O8; InChIKey WKJHPWJUFPYRSF-LEAZDLGRSA-N). PUG REST (opened 16 August 2026).
17. ClinicalTrials.gov API v2 query.term=pancragen and query.term=KEDW — empty studies arrays (opened 16 August 2026).
18. NCATS Inxight substances search pancragen — total 0 (opened 16 August 2026).
19. openFDA Drugs@FDA / labels pancragen — HTTP 404 (opened 16 August 2026).
20. IUPHAR ligand API pancragen and KEDW — HTTP 404 (opened 16 August 2026).
21. SRP product page (opened 16 August 2026): http://simpleresearchpeptides.com/product/pancragen-20-mg/
22. SRP compound index (opened 16 August 2026): http://simpleresearchpeptides.com/research-compound-directory/compound-research-guides/
23. SRP dedicated guide URL — HTTP 404 (opened 16 August 2026): http://simpleresearchpeptides.com/research-compound-directory/pancragen-research-guide/

Cited by an opened PMC page but not itself opened: Khavinson VK, Tendler SM, Kasyanenko NA, et al. Tetrapeptide KEDW interacts with DNA and regulates gene expression. *Am J Biomed Sci.* 2015;7:156–169. DOI 10.5099/aj150300156 (cited as ref. 42 in PMID 34834147). No PMID assigned on the citing page. Not used beyond what PMID 34834147 printed.

–-

These are intellectual-property documents, not peer-reviewed trials.

PubChem CID 57562370 xrefs include US07491703-20090217-C00001_1 and US20070142298A1-20070621-C00001_1, which ties that DL-amide CID to this patent family. That is a patent-structure deposit, not proof of an all-L SRP vial.

Patent Example 8 (36 patients, IM 10 µg or oral 100 µg tablet language) is patent-internal clinical narrative. No NCT. No PubMed RCT. Not used as registered-trial evidence and not used as a disease-treatment claim.

–-

ClinicalTrials.gov API v2 opened 16 August 2026:

• query.term=pancragen → totalCount 0
• query.intr=pancragen → totalCount 0
• query.term=KEDW OR "Lys-Glu-Asp-Trp" OR lysyl-glutamyl-aspartyl-tryptophanamide → totalCount 0

NCT: none found. No NCT ID is assigned. The Korkushko 2011 opened abstract and the patent Example 8 series are not registry trials.

–-

• NCATS Inxight search pancragen: total 0. Exact "PANCRAGEN": total 0. KEDW: total 0.
• openFDA Drugs@FDA pancragen: 404 / no matches. Labels: NOT_FOUND.
• IUPHAR ligand pancragen: 404. KEDW: no ligands.
• FDA UNII search page for Pancragen: no UNII card returned.
• PubChem has no CID titled Pancragen and CID 57562370 has no UNII / no CAS RN on the opened PUG xrefs.
• US7491703B2 states the tetrapeptide “was experimentally proved to be non-toxic.” That is patent language, not an FDA review.
• SRP and this draft: laboratory research only. Not for human or animal use.

–-

Almost every Pancragen PMID is from the originating St. Petersburg / Kiev / Sochi network. The cell-culture papers use human embryonic or passaged pancreatic cells — that is human tissue, not a clinical trial. The monkey papers are n=9 and n=old-animal glucose-load designs. The only opened human series (Korkushko 2011) is a short English abstract without dose, route, or trial-registration details. The only other human “treatment” narrative opened here sits inside a patent. There is no NCT, no UNII, no NCATS record, no IUPHAR ligand, no Drugs@FDA hit, and no PubChem CID titled Pancragen. Amide vs free acid is unresolved on the SRP page. Sequence confirmation of any research vial remains a laboratory identity step. Marketplace CAS 175026-95-2 was not verified on opened PubChem. Author sentences that call Pancragen a treatment for diabetes or pancreatitis are not adopted on this page.

–-

–-

Pancragen 20 mg — http://simpleresearchpeptides.com/product/pancragen-20-mg/ Opened page title: “Pancragen 20 mg Research Peptide Vial”. Breadcrumb/tags: Metabolic Research, Peptide Bioregulators, Research Peptides. Lead line: “one 20 mg research vial; verify sequence, salt form, and assay. Organized for pancreatic-tissue models, metabolic signaling, and peptide-bioregulator characterization. For laboratory research use only.” Description: research material Pancragen; listed strength and format 20 mg; research category Metabolic Research. Footer: “For laboratory research only. Not for human or animal use, consumption, administration, diagnosis, treatment, or therapeutic application.” Reviews (0). Sequence, CAS, UNII, molecular formula, amide status, and a public COA were not printed on the fetched page. A listed dollar price was not in the fetched body.

Index entry — http://simpleresearchpeptides.com/research-compound-directory/compound-research-guides/ Listing: “Pancragen 20 mg” under Metabolic; “Evidence profile.” Evidence tag: Sparse/limited evidence. Last editorial review printed: August 2026.

Dedicated guide — http://simpleresearchpeptides.com/research-compound-directory/pancragen-research-guide/ HTTP 404 on 16 August 2026.

–-

Sources actually opened for this draft:

1. Zakutskiĭ AN, Chalisova NI, Ryzhak GA, Aniskina AI, Filippov SV, Zeziulin PN. The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats. *Adv Gerontol.* 2006;19:93–96. PMID 17152728. Names pancragen. No DOI on the opened record.
2. Khavinson VKh, Gavrisheva NA, Malinin VV, Chefu SG, Trofimov EL. Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus. *Bull Exp Biol Med.* 2007;144(4):559–562. PMID 18642713. DOI 10.1007/s10517-007-0377-3. Sequence Lys-Glu-Asp-Trp-NH2.
3. Khavinson VKh, Gapparov MM, Sharanova NE, Vasilyev AV, Ryzhak GA. Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide. *Bull Exp Biol Med.* 2010;149(3):351–353. PMID 21246099. DOI 10.1007/s10517-010-0944-x. Trade name not on opened abstract.
4. Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA, Bondarenko EV. Prospects of using pancragen for correction of metabolic disorders in elderly people. *Bull Exp Biol Med.* 2011;151(4):454–456. PMID 22448364. DOI 10.1007/s10517-011-1354-4. Opened abstract only; not an NCT.
5. Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Peptides tissue-specifically stimulate cell differentiation during their aging. *Bull Exp Biol Med.* 2012;153(1):148–151. PMID 22808515. DOI 10.1007/s10517-012-1664-1. pancragen (Lys-Glu-Asp-Trp) vs bronchogen vs vesugen.
6. Khavinson VKh, Sevost’ianova NN, Durnova AO, Lin’kova NS, Tarnovskaia SI, Dudkov AV, Kvetnaia TV. Tetrapeptide stimulates functional activity of the pancreatic cells in aging. *Adv Gerontol.* 2012;25(4):680–684. PMID 23734516. DOI 10.1134/s2079057013030053. Sequence H-Lys-Glu-Asp-Trp-NH2.
7. Khavinson VKh, Durnova AO, Polyakova VO, Tolibova GH, Linkova NS, Kvetnoy IM, Kvetnaia TV, Tarnovskaya SI. Effects of pancragen on the differentiation of pancreatic cells during their ageing. *Bull Exp Biol Med.* 2013;154(4):501–504. PMID 23486591. DOI 10.1007/s10517-013-1987-6.
8. Goncharova ND, Ivanova LG, Oganian TÉ, Vengerin AA, Khavinson VKh. Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys. *Adv Gerontol.* 2014;27(4):662–667. PMID 25946840. Sequence Lys-Glu-Asp-Trp. No DOI on the opened record.
9. Tarnovskaya SI, Yakutseni PP, Khavinson VKh. Study of interactions between DNA and tetrapeptides using methods of molecular mechanics. *Bull Exp Biol Med.* 2014;156(5):689–693. PMID 24770759. DOI 10.1007/s10517-014-2426-z.
10. Goncharova ND, Ivanova LG, Oganyan TE, Vengerin AA, Khavinson VK. Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys. *Adv Gerontol.* 2015;28(3):579–585. PMID 28509500. No DOI on the opened record.
11. Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. *Biochemistry (Mosc).* 2015;80(3):310–322. PMID 25761685. DOI 10.1134/s0006297915030062. Names KEDW, not Pancragen.
12. Khavinson VK, Lin’kova NS, Tarnovskaya SI. Short peptides regulate gene expression. *Bull Exp Biol Med.* 2016;162(2):288–292. PMID 27909961. DOI 10.1007/s10517-016-3596-7. KEDW → acct.
13. Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide regulation of cell differentiation. *Stem Cell Rev Rep.* 2020;16(1):118–125. PMID 31808038. DOI 10.1007/s12015-019-09938-8. Review; KEDW → pancreas.
14. Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of biologically active ultrashort peptides using POT and LAT carriers. *Int J Mol Sci.* 2022;23(14):7733. PMID 35887081. PMC9323678. DOI 10.3390/ijms23147733. Table 2: Pancragen (KEDW-NH2), ICM −23.47.
15. Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of transport of 26 biologically active ultrashort peptides via LAT and PEPT family transporters. *Biomolecules.* 2023;13(3):552. PMID 36979488. PMC10046148. DOI 10.3390/biom13030552. KEDW-NH2 scores; name Pancragen not printed.
16. US7491703B2 (Lys-Glu-Asp-Trp-NH2 tetrapeptide; C26H37N7O8; 575.62). Google Patents HTML opened 16 August 2026. Family: WO2005056580A1; EP1697401B1; RU2242241C1; US20070142298A1; CA2547873C.
17. PubChem CID 57562370 (H-DL-Lys-DL-Glu-DL-Asp-DL-Trp-NH2; C26H37N7O8; InChIKey WKJHPWJUFPYRSF-UHFFFAOYSA-N; synonym SCHEMBL13933760). PUG REST opened 16 August 2026. Not titled Pancragen.
18. ClinicalTrials.gov API v2 query.term=pancragen — empty studies array (opened 16 August 2026).
19. NCATS Inxight substances search pancragen — total 0 (opened 16 August 2026).
20. openFDA Drugs@FDA pancragen — HTTP 404 (opened 16 August 2026).
21. IUPHAR ligand API pancragen — HTTP 404 (opened 16 August 2026).
22. SRP product page (opened 16 August 2026): http://simpleresearchpeptides.com/product/pancragen-20-mg/
23. SRP compound index (opened 16 August 2026): http://simpleresearchpeptides.com/research-compound-directory/compound-research-guides/
24. SRP dedicated guide URL — HTTP 404 (opened 16 August 2026): http://simpleresearchpeptides.com/research-compound-directory/pancragen-research-guide/

Opened and not used as Pancragen efficacy: PMID 34834147 (systematic review abstract does not name Pancragen/KEDW); PMID 32019204 (Epitalon neurogenesis); PMID 37435573 (WWASKS COL5 peptide); PMID 39871657 (2025 stem-cell-peptide review); pancreatic-cyst / IPMN lexical hits in the raw Europe PMC pancragen set.

–-